Akorn today announced that it has signed a Purchase and Supply Agreement with Natco Pharma Limited, located in Hyderabad, India, to commercialize two ANDA oral drug products for cancer patients suffering from nausea and vomiting. The two drug
products will focus on the anti-emetic market, and have a current market size
of approximately $800 million. Natco will be responsible for the development and
manufacturing of both drug products, while Akorn will be responsible for marketing
and distribution in the hospital, clinic, and home healthcare markets in the United
States and Canada.